Doug Vander Weide is the Founder and Chief Executive Officer of Valiant Wealth, LLC, a boutique multi-family office and investment advisory firm he launched in 2008. With more than 35 years of experience, Doug advises business owners and high-net-worth families through firm offices in Franklin, Tennessee and West Des Moines, Iowa. Doug currently serves on the boards of Regenexx, SuckerPunch, and Bespoke Manufacturing Company (Chair), and previously served on the boards of Worldwide Stages and Data Builder, Inc. His board experience spans healthcare, manufacturing, consumer brands, technology, and media, with a focus on scaling founder-led companies and preparing organizations for growth capital and exit. As an investor, operator, and board leader, Doug brings a practical, execution-oriented perspective to capital formation and value creation, informed by decades of work alongside founders, boards, and investors.

Dr. Christopher J. Centeno, M.D. is a specialist in regenerative medicine and has helped found the emerging specialty of Interventional Orthobiologics. He has had many world-wide and U.S. procedural firsts in Orthobiologics and is CMO of Regenexx and a founding member of the Interventional Orthopedics Foundation (IOF). He is one of the few physicians in the world with extensive experience in the culture expansion of and clinical use of adult stem cells to treat orthopedic injuries. He is responsible for the world’s largest and oldest stem cell treatment registry focused in the field of orthopedic injuries. His clinic incorporates a variety of Orthobiologic injections that are delivered via precision, image guidance to help patients from all over the world avoid more invasive orthopedic surgery. Dr. Centeno also runs lab and clinical research groups that have the benefit of a state-of-the-art cell biology research facility.

Dr. Centeno has chaired multiple international research-based conferences. He also maintains an active research-based practice, producing multiple publications per year that are listed in the US National Library of Medicine. Dr. Centeno has also served as editor-in-chief of a medical research journal dedicated to traumatic injury and serves as a peer reviewer for multiple research publications. He has lectured all over the world on regenerative therapies including twice at the Vatican in Rome.

Dr. Centeno trained at the Baylor College of Medicine, Texas Medical Center and the Institute for Rehabilitation Research.

Dr. Jerome Adams, M.D., MPH, is an anesthesiologist and former U.S. Surgeon General (2017-2021) who is currently a Presidential Fellow and Executive Director of the Center for Community Health Enhancement and Learning at Purdue University. His career has focused on public health and health equity, previously serving as Indiana’s State Health Commissioner before his national appointment. During his tenure as Surgeon General, he led the nation’s response to America’s opioid over prescribing and overdose crises and other public health crises.

Bill (W.K.) Abington III is a seasoned operations executive who has spent more than two decades at Medline Industries, serving most recently as Executive Vice President and President of Global Operations prior to Medline’s $30B+ sale to private equity. Prior to Medline, he built his financial leadership experience at International Paper, holding roles including Director of Finance at the Masonite Corporation division, Controller of Androscoggin Mill, and Auditor. He earned a Bachelor of Science in Accounting from the University of Mississippi.

Susan Stewart has more than 35 years of experience in biopharmaceutical regulatory affairs and quality assurance, overseeing and developing innovative regulatory strategies and leading interactions with global health authorities for drugs and biologics aimed at addressing unmet medical needs. In addition to being an independent regulatory consultant for several years, she serves as fractional Chief Regulatory Officer (CRO) for Rezolute Bio and Candel Therapeutics. Previously Sue served as CRO at Frequency Therapeutics, CRO at Kaleido Biosciences, Senior Vice President of regulatory affairs, quality and compliance at Tokai Pharmaceuticals, and Vice President, regulatory affairs at Transmolecular Therapeutics. She also spent 13 years at Genzyme Corporation (Sanofi) ultimately serving as Vice President, regulatory affairs after beginning her career with Abbott Laboratories in regulatory and quality positions. She is the Regulatory Advisor for The Termeer Institute, and as a guest lecturer at Stanford University, MIT and Harvard Medical School she shares her knowledge of regulatory processes and strategy.

Dr. Mihir Kamdar is a Pain Medicine and Palliative Care Physician at Mass General Hospital and a member of the teaching faculty at Harvard Medical School. He previously served as the Section Head of Palliative Care, Assistant Medical Director of MGH Telemedicine, and the Director of the Mass General Cancer Pain Clinic. He currently serves as the Head of Clinical Delivery for Tuesday Health. He earned his medical degree from Emory University School of Medicine and completed an internal medicine residency at Brigham and Women’s Hospital. He then pursued advanced training through the Harvard Palliative Medicine Fellowship, followed by a second fellowship in Interventional Pain at Mass General Hospital. His clinical and research work focuses on developing new approaches to treating refractory pain and on developing innovative treatment models for symptom and advanced-illness management. His work has been featured in publications including the New England Journal of Medicine, the Journal of the American Medical Association (JAMA), and the Wall Street Journal.

Dr. Ralph Vassallo is Executive Vice President and Chief Scientific and Medical Officer at Vitalant, where he oversees medical strategy, donor health programs, clinical oversight of operations, hospital consultation support, and the organization’s research portfolio. Before joining Vitalant, he was chief medical officer for the East Division of the American Red Cross Blood Services and previously served on the hospital leadership team at Jefferson Health Northeast in Philadelphia. Dr. Vassallo sits on the board of the Biomedical Excellence for Safer Transfusion Collaborative, contributes to the editorial boards of multiple journals and reference texts, and has led several committees for the Association for the Advancement of Blood and Biotherapies (AABB). He is the author of 100+ published chapters, articles, and reviews.

Dr. Li is a veteran CMC executive with nearly 30 years of experience in product development and manufacturing, shaping both technical and strategic decisions across CMC functions and external collaborations. She now works as an independent consultant after a long career in the pharmaceutical and biotech industries. Most recently, she held senior leadership roles as Chief Technology Officer and Senior Vice President at Magenta Therapeutics, Xilio Therapeutics, and DynamiCure Biotechnology, where she built CMC and technical operations teams and guided product development strategy.

Between 2017 and 2020, Li served as Vice President of Biologics Development and Manufacturing at Celgene, overseeing global technical development and manufacturing for all biologics programs. She built an organization of more than 150 scientists and engineers with an annual budget over $100 million and led CMC development for 15 biologics programs, culminating in the approval of REBLOZYL, Celgene’s first biologic therapy.

Earlier, she was Director and Head of Process Sciences at AbbVie, leading a team responsible for biologics development from clinical to commercial stages, including Humira. Prior to that, she held a series of R&D leadership roles at AbbVie and Abbott supporting small-molecule CMC development and discovery.